NCT02696148 - A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

April 13, 2017

Study Completion Date

April 13, 2017

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

liraglutide

For subcutaneous (s.c., under the skin) injection once daily.

DRUG

placebo

For subcutaneous (s.c., under the skin) injection once daily.

Trial Locations (9)

Novo Nordisk Investigational Site, Mineola

Novo Nordisk Investigational Site, Buffalo

Novo Nordisk Investigational Site, Pittsburgh

Novo Nordisk Investigational Site, Atlanta

Novo Nordisk Investigational Site, Jacksonville

Novo Nordisk Investigational Site, Pensacola

Novo Nordisk Investigational Site, Memphis

Novo Nordisk Investigational Site, Anaheim

Novo Nordisk Investigational Site, New Haven